Circulating Immunes Cells, Cytokines and Brain Radiotherapy

NCT05082961 · tracked via the Priya Life Science France tracker

Sponsor

Centre Francois Baclesse

Phase

Not applicable

Started

2022-01-27

Last updated

2024-12-11

Condition(s) studied

Head and Neck Cancer

Investigational drug(s) / intervention(s)

Collection of blood samples

Collection of blood samples: Samples to evaluate the circulating CD8+ T cell count.

Study summary

Patients with malignant tumours of the cephalic pole have a poor prognosis, despite a wide range of treatments. prognosis despite a large therapeutic arsenal. Among this arsenal, radiotherapy (RT) is one of the standard treatments for these tumours. However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic tissue and can promote pro-tumour inflammation.

In these circumstances, hadrontherapy, which uses charged heavy particles, such as protons or carbon ions, is the preferred treatment. protons or carbon ions, seems more appropriate for the treatment of these tumours. However, although inflammation plays a major role in tumour development and tumour development and therapeutic response, few studies have evaluated the immune response response after proton therapy (PT) and carbon therapy (CT). The objective of this project is to study the effect of hadrontherapy on resident/circulating inflammation after brain irradiation. brain irradiation. In a first step, the impact of different PT and CT TEL on macrophages (M\Ф), the most abundant immune cells in malignant solid tumours, will be evaluated in vitro. malignant solid tumours, will be evaluated in vitro. In a second step, the evolution of circulating leukocytes after brain irradiation with X-rays or protons will be studied in vivo in rodents and patients. rodent and patient. In this project, we propose to study for the first time the inflammatory response after hadrontherapy in the context of a cephalic tumour. cephalic tumour. These results will allow a better understanding of the biological response response following PT and CT with the aim of optimising RT and potentially and potentially translate these data to the clinic.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients \> 18 years * Head and neck cancer: (upper aerodigestive tract, cavum, facial sinus, skull base, brain) operated * Surgery for complete tumour resection or with microscopic residue R1 * All possible histologies: squamous cell carcinoma, undifferentiated carcinoma of the nasopharyngeal type (UCNT), adenocarcinoma, adenoid cystic carcinoma, chordoma, chondrosarcoma,meningioma other tumours * Patients undergoing exclusive postoperative radiotherapy with a minimum total dose of 54 Gy of X-ray photon radiation or equivalent proton radiation. * Patient affiliated to a social security scheme * Signature of the informed consent before any specific procedure related to the study Exclusion Criteria: * Macroscopic postoperative tumour residue R2 * Previous cancer within 5 years (except treated basal cell skin carcinoma and treated cervical cancer). * Previous radiotherapy (except brachytherapy of the cervix or prostate) * Chemotherapy or other systemic oncological treatment (cetuximab) concomitant with radiotherapy * Long-term immunosuppressive or corticosteroid therapy * Patient deprived of liberty or under guardianship, protected adult * Patient unable to undergo trial monitoring for geographical, social or psychopathological reasons * Pregnant or breastfeeding woman * Emergency situations

Primary outcome measure(s)

CD8+ T-cell count. — up to 3 months

Trial sites (1)

Facility	City	Region	Status
Centre François Baclesse	Caen	France	Recruiting

More Centre Francois Baclesse trials in France

TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma Recruiting

Interest of a Weekly Consultation by a Medical Electro Radiology Manipulator (MERM) in Addition to the Follow-up by the Radiotherapist to Improve the Collection of Radio-induced Toxicities in Patients Undergoing Proton Therapy Active, not recruiting

Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study Recruiting

Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery Recruiting

Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management Recruiting

Other trials for the same condition

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting

Nutritional Course of Care After Surgical Treatment at the Patients Affected by a Cancer of the Head and by the Neck Recruiting

Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO Active, not recruiting

Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05082961 on ClinicalTrials.gov ↗ ← All trials in France